Skip to main content
TipRanks
Go Ultimate75% OFF

Haemonetics (HAE) Q2 2027 Earnings Report

451 Followers

HAE Q2 2027 EPS Results

Actual EPS
$1.35
Consensus EPS
$1.29
Beat/Miss
Beat by +$0.06
One Year Ago EPS
$1.27

HAE Q2 2027 Revenue Results

Actual Revenue
$357.76M
Expected Revenue
$345.15M
Beat/Miss
Beat by +$12.61M
YoY Revenue Growth
+9.30%

Earnings Announcement Details

Quarter
Q2 2027
Date
11/05/2026
Time
Before Open
Conference Call
Thursday, November 5, 2026
HAE Upcoming Earnings

Haemonetics's next earnings date is estimated for February 11, 2027, based on past reporting schedules.

Q2 2027 Earnings Call Audio

HAE Q2 2027 Earnings Call
0:00 / 0:00

Q2 2027 Earnings Slide Deck

Q2 2027 Earnings Call Summary

Q2 2027
Earnings Call Date:Nov 05, 2026|% Change Since:-5.10%|
Earnings Call Sentiment|Positive

The call was strongly positive overall. The company reported double-digit organic growth in several areas, raised full-year revenue guidance, expanded its CSL relationship, advanced multiple product launches and regulatory approvals, and generated substantial cash flow. The main challenges were lower expected operating margin expansion, higher operating expenses and ramp-related costs, modest weakness in other apheresis, and uncertainty around second-half plasma collection volumes. Management nevertheless expressed confidence in the long-term growth runway and future operating leverage.

Company Guidance

For fiscal 2027, Haemonetics reaffirmed MedSurg organic revenue growth guidance of mid-single digits and raised apheresis organic revenue growth guidance to high single digits from low to mid-single digits; total company organic growth guidance increased to 6%-9% from 4%-7%, and reported growth guidance to 8%-11% from 5%-8%. The company now expects adjusted operating margin expansion of 0-50 basis points, compared with 50-100 basis points previously, and adjusted earnings per diluted share growth in line with its increased reported revenue growth guidance of 8%-11%. Free cash flow conversion is expected to be in excess of 80% of adjusted net income, with second-half growth weighted towards Q4, and guidance does not include any incremental revenue contribution from second-half plasma collections growth.

  • Strong Second-Quarter and First-Half PerformanceOrganic revenue growth was 10% in the second quarter and 8% in the first half. Adjusted earnings per share was $1.35 in the quarter and $2.49 in the first half, with adjusted EPS growth of 6% in both periods.
  • Fiscal 2027 Revenue Guidance IncreasedThe company raised fiscal 2027 organic revenue growth guidance to 6%-9% from 4%-7% and reported growth guidance to 8%-11% from 5%-8%.
  • MedSurg Delivered Broad-Based GrowthMedSurg organic revenue increased 6% in both the second quarter and first half. The company reaffirmed fiscal 2027 MedSurg organic revenue growth guidance of mid-single digits.
  • Blood Management Growth and Recurring Revenue ExpansionBlood Management Technologies grew 7% organically in the second quarter and 8% in the first half. Hemostasis management benefited from greater account penetration, higher TEG utilization, and continued share gains, while transfusion management revenue grew well into the double digits in both periods.
  • TEG Disposable Utilization MomentumThe TEG 5000 capital upgrade cycle is winding down, while recurring TEG 6s disposables grew at a mid-teens rate. TEG disposables represented 85% of the business, and disposable use per device has more than doubled as the product has been positioned as a site-of-care device.
  • Interventional Technologies Returned to GrowthInterventional Technologies grew 3% organically in both the second quarter and first half, sustaining the return to growth established in the first quarter.
  • Vascular Closure Share GainsVASCADE MVP and VASCADE MVP XL grew in the low double digits in electrophysiology in both the second quarter and first half. Strong demand, improved commercial execution, regulatory approvals, and greater utilization supported share gains as the underlying market stabilized.
  • New Product Launches and Regulatory ApprovalsThe company extended VASCADE MVP XL globally through initial CE Mark certification and Japanese regulatory approval, launched the PacePro guidewire, and received U.S. FDA approval for PerQseal Elite for large-bore structural heart and endovascular procedures.
  • Apheresis and Plasma GrowthApheresis organic revenue grew 14% in the second quarter and 10% in the first half. Plasma revenue grew 18% and 13%, respectively, driven by prior share gains, strong underlying collections, and the rollout of Persona PLUS.
  • Persona PLUS Adoption and Customer BenefitsThe Persona PLUS rollout is on schedule with substantial adoption across the customer base. The platform is stated to increase plasma yield, improve center productivity, lower customers' cost per liter, and deliver approximately 5% or 6% incremental yield per collection on average for some collectors.
  • Expanded CSL RelationshipThe company expanded its CSL relationship, with CSL taking the full Persona PLUS suite and updated software offerings. Haemonetics began full-scale conversion in October and anticipates completing the rollout of NexSys PCS with Persona PLUS to all of CSL's U.S. plasma centers before the end of calendar 2027.
  • Long-Term CSL Growth OpportunityManagement described CSL as a multi-year opportunity for accelerated revenue and earnings growth, with converted centers expected to contribute recurring disposable use and provide a base for future product upgrades. Management stated that plasma volume could increase by approximately 50% as the relationship scales.
  • Plasma Collection GrowthSecond-quarter global plasma collections grew in the high single digits. U.S. collections tracked in the mid to high single digits, while outside-the-U.S. collections were tracking well into the double digits.
  • Improved Gross MarginSecond-quarter adjusted gross margin increased approximately 140 basis points year over year to 61.9%. First-half adjusted gross margin increased approximately 60 basis points to 61.2%, supported by favorable portfolio mix and the second-quarter tariff refund.
  • Strong Cash GenerationFirst-half operating cash flow increased 40% year over year to $180 million, while free cash flow increased approximately 57% to $143 million despite higher capital expenditures. Free cash flow conversion was 166% in the quarter and 111% of adjusted net income on a trailing 12-month basis.
  • Balance Sheet Flexibility and Debt RepaymentThe company ended the quarter with approximately $261 million in cash and estimated net leverage of approximately 2.5x EBITDA. It repaid $50 million on its revolver in the second quarter and $100 million year to date, with $325 million remaining under its existing share repurchase authorization.
  • Planned Capacity and Technology InvestmentsThe company is investing in manufacturing capacity, additional production lines, packaging, warehousing, devices, distribution readiness, Vivasure, new product launches, regulatory approvals, research and development, and technology capabilities to support growth and the CSL rollout.
  • No Impact from Reported European CyberattackManagement stated that Haemonetics was not affected by the reported cyberattack targeting certain plasma and blood banks in Europe and said safeguards were in place.

HAE Earnings History

HAE earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 11, 20272027 (Q3)1.26-1.31――
Nov 05, 20262027 (Q2)1.291.351.276.30% (+0.08)
Aug 06, 20262027 (Q1)1.081.141.13.64% (+0.04)
May 07, 20262026 (Q4)1.271.291.244.03% (+0.05)
Feb 05, 20262026 (Q3)1.251.311.1910.08% (+0.12)
Nov 06, 20252026 (Q2)1.111.271.1213.39% (+0.15)
Aug 07, 20252026 (Q1)1.011.101.027.84% (+0.08)
May 08, 20252025 (Q4)1.221.240.937.78% (+0.34)
Feb 06, 20252025 (Q3)1.171.191.0414.42% (+0.15)
Nov 07, 20242025 (Q2)1.071.120.9913.13% (+0.13)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed